INTRODUCTION

GENE AND FUNCTION
Protein C (PC) is a major component of the coagulation/fibrinolysis cascade. Circulating in plasma as an inactive zymogen, PC is activated at the endothelial surface by the membranebound thrombin-thrombomodulin complex. 1 When activated protein C (APC) is bound to its cofactor, protein S, it inactivates the procoagulant factors (F) FVa and FVIIIa, limiting the coagulation cascade and fibrin formation. 1, 2 PC activation is enhanced approximately 20-fold when PC binds to the endothelial protein C receptor (EPCR), 3 a type I transmembrane protein.
EPCR is primarily localized on the endothelial cells of large blood vessels (ie arteries and veins)
and is very sparse on or absent from the microvascular endothelium of most tissues. 4 EPCRbound APC triggers protease-activated receptor-1 cleavage, resulting in anti-inflammatory and cytoprotective (eg anti-apoptotic) effects. 2, 5 In addition to its APC-mediated effects, EPCR also works to limit thrombus formation by binding procoagulant FVII/FVIIa, facilitating the clearance of FVIIa and limiting downstream activation of the tissue factor (extrinsic) coagulation pathway. 6, 7 Together, these elements strongly favour an important role for EPCR in thrombosis and inflammation. 1 A soluble form of EPCR (sEPCR) also circulates in plasma. sEPCR binds PC/APC with the same affinity as membrane-bound EPCR, but does not enhance PC activation by the thrombinthrombomodulin complex. 8 Furthermore, sEPCR-bound APC is incapable of inactivating FVa, 8 and may also impede protease-activated receptor-1 cleavage. 2 By limiting APC generation and function, elevated levels of sEPCR may exert procoagulant and proinflammatory effects; in two
For personal use only. on . by guest www.bloodjournal.org From case-control studies, 9 , 10 elevated levels of sEPCR were associated with increased risk of VTE.
Likewise, a small family study found a higher occurrence of VTE in those with above-normal values of sEPCR, compared to those with normal levels.
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The PROCR gene is located on chromosome 20q11.2, spans 6 kilobases, and possesses four exons. 12 The mature protein comprises 221 amino acids, including an extracellular domain, a 25-amino acid transmembrane domain, and a 3-amino acid intracytoplasmic sequence. Animal experiments have demonstrated the importance of PROCR in normal embryonic development; in PROCR knock-out mice, fibrin deposition in trophoblast giant cells results in thrombosis at the maternal-embryonic interface. 13 Death occurs by embryonic day 10.5.
GENE VARIANTS AND FREQUENCY
Mutations in the PROCR gene that influence protein expression, function, and/or the concentration of sEPCR may be functionally relevant. Rare point mutations in the gene 14 and its promoter region 15 have been described, but effects on thrombosis and gene expression remain unknown. 16 The rs867186 diallelic single nucleotide polymorphism (SNP) in the PROCR gene (g.6936A>G,
c.4600A>G), resulting in a serine to glycine substitution at codon 219 in the membrane-spanning domain of EPCR, explains between 56% and 87% of variation in sEPCR levels. 10, [17] [18] [19] The G allele tags the A3 haplotype (four PROCR haplotypes have been identified in Caucasians) and is associated with increased shedding of EPCR from the endothelial membrane both by rendering the receptor more sensitive to cleavage 20 and by leading to a truncated mRNA through alternative splicing. 21 The overall frequency of the G allele is 0.074 among individuals included to date in the 1000 Genomes Project; 22 however, large variation across the population exists (eg including genetic determinants such as the Factor V Leiden (F5L) and prothrombin G20210A gene mutations 28, 29 and variants in the ABO gene, 30, 31 as well as age, obesity, hypertension, diabetes mellitus, smoking, and hypercholesterolemia. 32 All of these risk factors increase susceptibility to thrombus formation by modifying the coagulation and fibrinolytic systems. 33 The PROCR rs867186 variant has emerged as a candidate risk factor for both arterial and venous thrombotic disease because of the involvement of EPCR in APC-and FVII/FVIIa-mediated clotting and inflammation. However, evidence for an association between the PROCR rs867186
For personal use only. on . by guest www.bloodjournal.org From variant and arterial and venous thrombosis has been conflicting. We therefore undertook a systematic review and meta-analysis of observational studies to evaluate the evidence for an association between the PROCR rs867186 variant and two common thrombotic outcomes, VTE and MI, which are hypothesized to share etiologic pathways. Although ischemic stroke is also a common thrombotic outcome, we chose not to include it in our review because the outcome was highly variable (ischemic and haemorrhagic stroke cases were often indistinguishable) and because the number of studies of stroke was low.
MATERIALS AND METHODS
SEARCH STRATEGY
MEDLINE, EMBASE, and the HuGE Navigator Genopedia database were searched through July 2011 using a combination of keywords, including "thromboembolism", "thrombosis", "pulmonary embolism", "myocardial infarction", "EPCR", and "PROCR" (Supplementary Table   1 ). Titles and abstracts of identified articles were screened by two reviewers, and those that discussed any PROCR variant in the context of VTE or MI proceeded to full text screen. The full text of articles was screened by two reviewers and case-control, cohort, or cross-sectional studies examining an association between the PROCR rs867186 polymorphism and VTE or MI were selected for inclusion, with disagreements resolved by consensus. Reference lists of included studies and review articles were searched for additional articles. Genetic linkage studies, review articles, animal studies, and conference proceedings were excluded.
GWAS of VTE or MI in which the PROCR rs867186 variant, or variants in close linkage disequilibrium with rs867186, might potentially have been included on the genotyping platform For personal use only. on . by guest www.bloodjournal.org From were located using keyword searches of the HuGE Navigator GWAS Integrator database.
Unpublished GWAS were identified by keyword searches of the National Center for Biotechnology Information database of genotypes and phenotypes (dbGaP). Authors of relevant GWAS were contacted to request counts of events and non-events by PROCR rs867186 genotype (ultimately, all identified GWAS had genotyped this SNP).
Information on study design, location, demographics and ascertainment of subjects, case definition, and genotype and allele frequencies was extracted from included studies by two independent reviewers using a standardized data abstraction form. When this information was not available from the article, it was sought from other publications reporting on the same study population, if available. Crude odds ratios (OR) and their 95% confidence intervals (CI) were calculated from genotype frequencies presented in the published article; when separate genotype counts were not presented, they were requested from the study authors.
META-ANALYSIS
Inverse variance-weighted random effects meta-analysis was used to estimate the summary effect and 95% CI for VTE, MI, and VTE and MI combined, using Stata version 11. The G allele was considered the at-risk allele, and the per-allele effect estimate was calculated as the odds ratio per unit score (0, 1, or 2 copies of the G allele) using logistic regression. The perallele odds ratio is the risk of disease per one-allele increase, and the P-value of the odds ratio tests the hypothesis of zero slope for a line that best fits the three genotypic risk estimates. 34 The per-allele model is powerful for detecting additive genetic effects 34 and the additive model is in accordance with the observed variation in sEPCR values according to the number of copies of the G allele. 18, 19, 35 In secondary analyses, four additional genotype contrasts were tested for Four subgroup analyses were subsequently carried out to explore possible explanations for heterogeneity. In the first, GWAS were excluded from the meta-analysis; in the second, candidate gene studies were excluded from the meta-analysis; in the third, analyses were restricted to studies of white populations; in the fourth, studies with deviation from HardyWeinberg Equilibrium (HWE), a potential indicator of poor genotyping quality or ascertainment issues, were removed. HWE was investigated in controls of case-control studies, and in the entire samples of cohort studies, using the standard chi-square goodness of fit test as well as the relative excess heterozygosity (REH). 38 The chi-square goodness-of-fit statistic tests the null hypothesis that the data are consistent with HWE. In contrast, the REH approach quantifies Hardy-Weinberg disequilibrium by measuring the ratio of the actual proportion of heterozygotes to the proportion of heterozygotes expected in a population which conforms to HWE. 38 A significant deviation of the ratio from unity, as measured by the two-sided 95% confidence interval, is evidence of Hardy-Weinberg disequilibrium. Among studies of MI, a fifth subgroup
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From analysis was carried out in which analysis was restricted to studies that had used a history of MI as the case definition.
The Venice criteria for assessing the strength of cumulative evidence in genetic association studies were used. 39 Briefly, this semi-quantitative index classifies the credibility of cumulative epidemiologic evidence into three categories -"weak", "moderate", and "strong" -taking into consideration criteria such as amount of evidence (eg sample size, power, false-discovery rate), replication (eg attention to phenotype definition, models, I 2 ), and protection from bias (eg population stratification, measurement errors). This review was prepared following the guidance of the HuGE Review Handbook, Version 1.0.
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RESULTS
The search of MEDLINE, EMBASE, and HuGE Navigator Genopedia returned 150 unique candidate gene articles, of which 12 (9 VTE, 3 MI) were eligible for inclusion ( Figure 1 ). The study populations overlapped in three studies of VTE 9, 17, 41 and so de-duplicated counts were obtained from one of the authors and included. The population in one study of MI 19 overlapped with that in the gene-centric meta-analysis 42 included in the systematic review (see below), and so this article was excluded from further analysis. A second candidate gene article, 43 as well as a gene-centric study of VTE identified from the reference list of a review paper, 44 was excluded because genotype counts were not available separately for each of the three genotype groups.
The search of HuGE Navigator GWAS Integrator returned 46 GWAS, of which 18 (1 VTE, 17 MI) were eligible for inclusion ( Figure 1 ). Contact with GWAS authors resulted in the identification of an additional gene-centric (>2000 genes) study in press. 42 This study, as well as the most recent GWAS of MI, 31 were meta-analyses that included 21 studies. Together, these two studies encompassed almost all of the previously published GWAS results. Therefore, no other GWAS of MI beyond these two meta-analyses were included in this systematic review.
Study-specific genotype counts were obtained from the GWAS meta-analysis 31 for use in the present meta-analysis. In the gene-centric meta-analysis, 42 because the per-allele OR was presented but genotype counts were not, the per-allele OR was used in the present meta-analysis. Characteristics of studies included in the meta-analysis are presented in Supplementary Table 2.
All 11 VTE studies employed a case-control design, of which two 9, 41 were family-based (controls were first-degree relatives of cases), one 45 was nested within a cohort study, and two 30, Heit 2011 were GWAS designs. Six studies 9, 17, 30, 35, 41 included white subjects only, three studies 45, 46 , Heit 2011 included white and non-white subjects, one study 47 included Chinese subjects, and one study 10 did not report the race/ethnicity of subjects. Cases and controls were matched by age and gender in six studies. 10, 35, 45-47, Heit 2011 In all but two non-matched studies, age and gender distributions were similar in cases and controls. 30 Two studies were of first-event VTE patients, 10, 30 all cases of VTE were objectively diagnosed, and the case definition included deep vein thrombosis (DVT) and pulmonary embolism (PE), except in two studies 10, 47 limited to DVT only. Cases were recruited from thrombosis clinics in eight studies, from a venous thrombosis registry in one study, 46 and from a community-based cohort in another study. 45 45 or from a clinical trial of antioxidant supplementation. 30 In one study 47 , the source of cases and controls was not stated.
The 14 MI studies included one cohort study, three case-control studies, nine GWAS casecontrol studies, and one case-control gene-centric meta-analysis (Supplementary Table 2 ).
Twelve studies included white subjects only; the remaining two studies presented results for white subjects and South Asian subjects separately. 18, 42 This stratification by race/ethnicity was maintained in the present meta-analysis, for a total of 16 MI studies analyzed. Cases and controls were matched by age and gender in three studies, 18, 31, 48 whereas the age and/or gender distribution of cases and controls was either not reported or differed considerably in all but one 42 of the other studies. One study was of first-event MI patients 18 and the case definition was a history of MI in six studies, whereas a composite case definition including coronary intervention procedures, angina, >50% stenosis of coronary vessels, and MI was used in the other 11 studies.
Cases and non-cases were population, hospital, or clinic based.
Genotype and minor allele frequency distributions were similar between studies (Table 1) , with the exception of the studies of South Asians. While the frequency of the G allele among controls or in the underlying cohort was 13% or less in white populations, the frequency was 19-21%
among South Asian controls. There was evidence of deviation from HWE in three studies (two of VTE 17, 45 and one of MI 48 ), with both methods of HWE assessment yielding similar conclusions.
VENOUS THROMBOEMBOLISM
The meta-analysis supported an association between the PROCR rs867186 variant and VTE ( Figure 2 , Table 2 (Table 3) .
Of the individual studies included in the meta-analysis, the largest association between the PROCR rs867186 variant and VTE was observed in a study 9 of prothrombin G20210A mutation carriers (per-allele OR=2.63, 95% CI: 1.41, 4.87). Although no other included study was conducted exclusively among these mutation carriers, seven other studies reported the prevalence of G20210A mutation carriers; the prevalence was less than 25% and no obvious gradient in the estimated odds ratios according to G20210A mutation prevalence was observed (Supplementary Table 3 , Supplementary Figure 2) . One included study was conducted exclusively among F5L mutation carriers. 41 Results from this study were null (per-allele OR=0.98, 95% CI: 0.54, 1.77).
A large positive association (per-allele OR=1.49, 95% CI: 1.17, 1.90) was observed in the study that included only idiopathic VTE subjects (ie VTE in the absence of acquired risk factors:
surgery, hospitalization, pregnancy, puerperium, oral contraception, cancer, and autoimmune disease; and in the absence of strong known genetic risk factors: antithrombin, protein S, or protein C deficiencies, and homozygosity for F5L or prothrombin G20210A). 30 In the seven other studies in which the etiology of VTE was reported, the proportion of idiopathic VTE subjects ranged from 25% to 65% and there was no obvious trend in the estimated odds ratios according to the frequency of idiopathic subjects.
MYOCARDIAL INFARCTION
The meta-analysis did not support an association between the PROCR rs867186 variant and MI ( Figure 3 , Table 2 ). None of the investigated genotype contrasts reached statistical significance.
Heterogeneity between MI studies under all genetic models was moderate to high (as above, the apparent low heterogeneity under the recessive model and for the GG vs AA contrast is likely the result of wide confidence intervals in analyses of GG subjects). No publication bias under the per-allele model was observed (Supplementary Figure 1) , with an Egger's test P-value of 0.25.
When the analysis was restricted to GWAS, under the per-allele model, the I 2 was reduced to 36% (95% uncertainty interval: 0, 68) and the odds ratio for MI was 0.93 (95% CI: 0.89, 0.98)
for every additional copy of the G allele (P= 0.005) ( Table 3 ). In all other subgroup analyses, heterogeneity remained moderate to high and the effect estimate was similar to that obtained from analysis of all subjects.
Of the 16 included studies of MI, a statistically significant association between increasing copies of the PROCR rs867186 G allele and MI was found in three; in one of these, the association was positive, and in the other two, there was an inverse association. The statistically significant positive association was observed in the study 18 Although initially intended, results of VTE and MI studies were not pooled together in a combined analysis because of differences in the direction of the association with the PROCR rs867186 G allele in VTE and MI studies.
DISCUSSION
This meta-analysis of 4821 VTE cases and 6070 controls found a significant association between the PROCR rs867186 variant and VTE. Under an additive genetic model, the odds of VTE increased by 22% for every additional copy of the G allele. In contrast, the meta-analysis found no association between the PROCR rs867186 variant and MI. With nearly 17,000 MI cases and over 43,000 non-cases, and based on our current knowledge of trait and variant characteristics (ie disease prevalence of approximately 4%, 49 population G allele frequency of approximately 10%, 24 and an additive disease model), the meta-analysis had >99% power to detect a per-allele effect as small as 1.1 at a significance level of 0.05 (Supplementary Table 4) , 50 if such an association existed. However, substantial between-study heterogeneity and other populationspecific characteristics may have reduced this theoretical power. Given the present results, the hypothesis of some common pathways underlying venous and arterial thrombosis may not apply to the PROCR gene and the variant may be a genetic risk factor for VTE only.
VENOUS THROMBOEMBOLISM
The association with VTE is in accordance with the proposed functional implications of the PROCR rs867186 variant, namely, the G allele causes EPCR shedding from the endothelial membrane, reduced protein C activation, and higher FVII/FVIIa levels, eventually leading to thrombosis. Of the eight studies included in the meta-analysis that examined levels of sEPCR relative to the PROCR rs867186 variant, all observed a significant increase associated with the G allele. observed a statistically significant increase in PC associated with the G allele, one study 9 observed a statistically significant decrease in APC among G allele carriers, and the fourth study 17 found no association between genotype and APC levels. In a GWAS of plasma levels of PC including over 8000 participants, the strongest association was observed at the PROCR locus, and the rs867186 polymorphism explained an estimated 10.4% of the variance in PC. 51 In two studies included in the systematic review that measured prothrombin (fragment 1 and 2) levels relative to genotype, a significant increase was seen for those with the G allele. 17, 18 The G allele was also associated with elevated levels of FVII and FVIIa in a study of approximately 2,000 healthy, middle-aged men. 6 VTE is multicausal, in that multiple genetic and environmental factors contribute to its etiology. 52 Two genetic risk factors for VTE with relatively high population prevalence are well established: the F5L and prothrombin G20210A mutations. The largest association between the PROCR rs867186 variant and VTE identified in our review was observed in a study of prothrombin G20210A mutation carriers. 9 However, further investigation of the modifying role of this mutation was hampered by the low prevalence, or incomplete reporting of the prevalence, of prothrombin G20210A mutation carriers in the other included studies. No association between the PROCR rs867186 variant and VTE was observed in two studies of F5L mutation carriers (only one of which was included in the review). 41, 43 In a study (not included in the review) of two families with inherited thrombophilia, a stronger association with VTE was observed in those with both the PROCR G allele and a dysfunctional PC variant, relative to those with a dysfunctional PC variant alone. 11 Although limited by the small number of studies, taken together, these findings suggest that the PROCR rs867186 polymorphism may act in concert with some known genetic risk factors, but not others, to increase VTE risk.
All but one study included in the meta-analysis 30 used a pooled definition of idiopathic and nonidiopathic VTE cases; only one study restricted the case definition to idiopathic VTE patients. In pooling idiopathic and non-idiopathic VTE cases, heterogeneity in the definition of the outcome may have weakened or even masked the effect of the PROCR rs867186 variant on VTE.
Providing some evidence for this is the fact that the study restricted to idiopathic VTE patients reported a large positive association with the G allele of PROCR rs867186.
MYOCARDIAL INFARCTION
Between-study heterogeneity in MI studies was moderate to high, as indicated by both the I 2 and
Cochran's Q statistics, and is likely attributable to differences in study design, participant selection, and participant characteristics. The meta-analysis pooled results of cohort, caseFor personal use only. on . by guest www.bloodjournal.org From control, and GWAS designs; in ten studies, the case definition included MI grouped with other coronary heart diseases, and the severity of MI (fatal versus non-fatal) varied or was unclear across studies. Two studies were restricted to men, some studies included younger subjects (eg <60 years of age), while the age and gender of subjects was not reported in the study of diabetics.
The I 2 was less among GWAS studies, but even among the nine GWAS in which information on subject characteristics was available, the frequency of cases with a history of MI ranged from 48% to 100%, the age and gender distribution of subjects varied considerably, and two studies were restricted to cases with a family history of coronary artery disease.
Although no overall association with MI was found, when analysis was restricted to GWAS under the per-allele model, a statistically significant inverse association with the PROCR rs867186 G allele emerged. This finding may be due to reduced heterogeneity in GWAS studies as a result of harmonization of the case definition, quality control measures, and analysis methods that occurs in consortiums, of which all of the GWAS studies were part. Our GWAS findings are consistent with a recently published (ie after our search was updated for the last time) gene-centric case-control study of Italian early-onset MI cases; 53 however, they are nonetheless difficult to explain. The biological mechanism underlying an inverse association between rs867186 and MI is unclear. It may be that the PROCR rs867186 G allele is in linkage disequilibrium with the true causal variant.
STRENGTHS AND LIMITATIONS
Strengths of the systematic review include the thorough search for articles, the investigation of both venous and arterial thrombotic disease, the large number of included subjects, and the use of a genetic model that is based on biological evidence. The limitations of the meta-analysis
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include the possible influences of selection bias and genotype and phenotype misclassification on the results of individual studies and on the results of the meta-analysis, which are difficult to predict. Bias could also have arisen when calculating the crude odds ratios from genotype frequencies, since this could not be taken into consideration in the analysis when cases and controls were matched. Nonetheless, unmatched effect estimates were almost identical to those presented in the published article, either because matched and unmatched analyses produced similar results or because the investigators had not performed a matched analysis. When estimates adjusted for potential confounders were presented in the published article, these too approximated the crude estimates calculated from genotype frequencies. A major source of confounding in genetic association studies, population stratification, was assessed in the metaanalysis by restricting analysis to white subjects only. Although confounding was not detected, the "white" designation may yet comprise individuals of varying race/ethnicity, and hidden population stratification cannot be completely ruled out.
While selective reporting must be considered in all meta-analyses, because of ready sample availability and low genotyping cost, it is especially a concern in studies of gene-disease associations in which authors may test many polymorphisms but only report the most interesting or statistically significant findings. Even the means by which publication bias is measuredfunnel plots and statistical tests of funnel plot asymmetry -have limited power. 40 Although no statistically significant publication bias was detected, it is nonetheless possible that studies with null findings were not published and are missing from the systematic review. In an attempt to overcome this limitation, we included in our search both published and unpublished GWAS data, and authors of all eligible studies were contacted to request genotype counts.
For
CONCLUSIONS
Applying the Venice criteria, 39 the strength of cumulative evidence for an association between the PROCR rs867186 variant and VTE is "moderate". The meta-analysis had >80% power to detect a per-allele relative risk of 1.15 (Supplementary Table 4 ), furthermore, there existed some between-study heterogeneity, and the effect of potential biases could not be completely assessed.
This corresponds to a score of "B" in each of amount of evidence, replication, and protection from bias. Using the same criteria, the strength of evidence for an association with MI is "weak". Despite a considerable sample size indicating large-scale evidence ("A" rating), there existed substantial between-study inconsistency in MI phenotype definition, study populations, and study findings, and a null overall effect was found ("C" rating for replication).
In light of the ever-increasing number of gene-disease association studies, especially in the post-GWAS era, HuGE reviews are a useful tool to summarize this data. Overall, there is moderate evidence for an association between the PROCR rs867186 polymorphism and VTE, whereas there is weak evidence for an association with MI. This suggests that a common mechanism underlying venous and arterial thrombosis is not mediated by the PROCR rs867186 polymorphism. 
TABLES
MAF indicates minor (G) allele frequency.
*
Studies are identified by the lead author's last name, year of publication, study name (if a publication included more than one study) and reference number. †
The MAF was calculated in controls or in the underlying cohort. ‡
The REH cannot be calculated in studies with 0 cases or controls with the GG genotype. § Genotype frequencies were not reported in the published article; however, the study authors state that SNP did not violate HWE in the controls (p>0.0001).
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